But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...

Ensifentrine is a promising supplementary therapeutic option in the management of chronic obstructive pulmonary disease (COPD), according to systematic review and meta-analysis findings published in ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

MRI of inhaled perfluoropropane can assess regional lung ventilation and monitor improvements in response to medication ...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to solidify AstraZeneca’s position in the market.

Individuals with early-onset COPD and rapidly progressive pre-COPD frequently have a decades-long history of impaired ...

The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...

People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...

New Study Shows Promising Results for COPD Treatment Nov. 20 ... have found that dual bronchodilators -- long-lasting inhalers that relax the airways and make it easier to breathe -- do little ...